Clinical efficacy of Atezolizumab/Bevacizumab combined with TACE in treating BCLC stage C hepatocellular carcinoma

BackgroundThe prognosis of advanced primary liver cancer [Barcelona Clinic Liver Cancer (BCLC) stage C] remains poor. Although atezolizumab plus bevacizumab (Ate/Bev) is a standard treatment, the potential of intensifying this regimen into a triple therapy by adding local intervention is unclear.Aim...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Lei Yuan, Xiao-Hong Yang, Zhi-Li Ma, Ning Fan, Gen-Shu Wang, Yan-Ling Zhu
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2026-03-01
Цуврал:	Frontiers in Oncology
Нөхцлүүд:	atezolizumab BCLC stage C bevacizumab hepatocellular carcinoma (HCC) neutrophil-to-lymphocyte ratio (NLR)
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1744076/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!